Cowen Reiterates Outperform Rating on Terns Pharmaceuticals (TERN), Believes VAP-1 is Not Well Understood and Could be Underappreciated
Tweet Send to a Friend
Cowen analyst Ritu Baral reiterated an Outperform rating on Terns Pharmaceuticals (NASDAQ: TERN), following the company's report of Phase 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
